PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
Hemodynamic assessment did not improve guidance for complete revascularization in multivessel stenting for patients with ST-segment elevation MI (STEMI), according to the FLOWER-MI trial.
Fractional flow reserve (FFR) was no better than angiography at guiding percutaneous coronary intervention (PCI) on nonculprit lesions in terms of 1-year clinical outcomes among more than 1,000 study participants, reported Etienne Puymirat, of the European Hospital of Georges Pompidou in Paris.
By then, the combined rate of all-cause mortality, MI, or unplanned hospitalization leading to urgent revascularization was similar between patients randomized to FFR or angiographic guidance (5.5% vs 4.2%, HR 1.32, 95% CI 0.78-2.23). There were no differences in individual endpoint components either, Puymirat said at the American College of Cardiology (ACC) virtual meeting. FLOWER-MI results were simultaneously published in the
Etripamil Nasal Spray Reduced ER Vistsis and More PSVT Resolution in New NODE-301 Analysis
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions.
May 16, 2020 New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve paroxysmal supraventricular tachycardia (PSVT) found the drug helps reduce emergency room visits and significantly reduced symptoms as compared to placebo. This was the finding of a new post-trial data analysis presented at the American College of Cardiology (ACC) 2021 virtual scientific session.
(1)
PALO ALTO, Calif., May 16, 2021 /PRNewswire/ ReCor Medical, Inc. ( ReCor ), a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., today presented the primary endpoint data from the randomized sham-controlled RADIANCE-HTN TRIO ( TRIO ) study. In subjects with resistant hypertension, those treated with the Paradise Ultrasound Renal Denervation System had a greater drop in blood pressure than those who received a sham procedure. TRIO results were presented today at the American College of Cardiology meeting (https://accscientificsession.acc.org/) and published simultaneously in The Lancet.
The TRIO study evaluated the efficacy and safety of the Paradise Ultrasound Renal Denervation System in hypertensive patients who were all treated with a single pill containing 3 standardized anti-hypertension medications (a calcium-channel blocker, an angiotensin II receptor blocker, and a thiazide diuretic). After confirmation of inadequately controlled hypertension despite these
May 15, 2021
The estimated 1-year rate of ischemic stroke after implantation of the Watchman left atrial appendage (LAA) closure device (Boston Scientific) was 1.53% in its first few years of commercial use in the United States, which encompassed a relatively high-risk population of patients with atrial fibrillation (AF), registry data show.
That’s substantially lower than would be expected in a cohort of patients with a similar thromboembolic risk based on CHA
2DS
2-VASc score who are not taking oral anticoagulation (6.64%), Matthew Price, MD (Scripps Clinic, La Jolla, CA), reported Saturday during the virtual American College of Cardiology (ACC) 2021 Scientific Session.
The low thromboembolic event rate observed in the study, which used information from the ACC’s National Cardiovascular Data Registry (NCDR) LAAO Registry, “supports the early-to-midterm clinical effectiveness of transcatheter LAAO as it is being currently utilized in the United States,” Price said.